Loading...
Docoh

ContraFect (CFRX)

Utility
Antibodies Useful In Passive Influenza Immunization, and Compositions, Combinations and Methods for Use Thereof
14 Apr 22
Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus.
Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
Filed: 23 Dec 21
Utility
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
15 Feb 22
Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus.
Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
Filed: 5 Nov 19
Utility
Blood Component Potentiation of Lytic Protein Anti-bacterial Activity and Methods and Uses Thereof
27 Jan 22
The present invention provides methods, assays, compositions, formulations, and constructs, particularly lytic peptide constructs, which relate to and are based on the activity and use of blood components, particularly serum albumin and lysozyme, and their activity and use to enhance or synergize with the bacterial killing effect of anti-bacterial lytic proteins and peptides.
Raymond SCHUCH
Filed: 10 Jul 18
Utility
Compositions and Methods Comprising Lysocins As Bioengineered Antimicrobials for Use In Targeting Gram-negative Bacteria
27 Jan 22
Provided are polypeptides and compositions comprising the polypeptides for use in killing and/or inhibiting growth of Gram-negative bacteria, particularly P. aeruginosa.
Vincent FISCHETTI, Ryan D. HESELPOTH, Raymond SCHUCH, Chad EULER
Filed: 4 Nov 19
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
25 Nov 21
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond SCHUCH
Filed: 23 Aug 19
Utility
Antimicrobial, Bacteriophage-derived Polypeptides and Their Use Against Gram-negative Bacteria
28 Oct 21
Disclosed herein are pharmaceutical compositions comprising an effective amount of an isolated Chp peptide having an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-4, 6-26 and 54-66, or a modified Chp peptide having about 80% sequence identity therewith, wherein the modified Chp peptide inhibits growth, reduces the population, or kills at least one species of Gram-negative bacteria; and a pharmaceutically acceptable carrier.
Raymond SCHUCH
Filed: 29 Mar 19
Utility
Use of Gram-negative Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs In Treating Endocarditis
21 Oct 21
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond SCHUCH
Filed: 22 Dec 20
Utility
Lysin CF-301 Resensitizes Methicillin-resistant Staphylococcus Aureua (Mrsa) to Penicillin Derivatives and First Generation Cephalosporins
26 Aug 21
Disclosed are methods of resensitizing a Gram-positive bacterium in a subject to at least one β-lactam antibiotic, comprising co-administering the Gram-positive bacterium with the at least one β-lactam antibiotic and a lysin polypeptide, thereby resensitizing the Gram-positive bacterium in the subject to the at least one β-lactam antibiotic.
Raymond SCHUCH
Filed: 21 Jun 19
Utility
Use of Gram-negative Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs In Pulmonary Surfactant and Biofilms
20 May 21
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond SCHUCH
Filed: 22 Dec 20
Utility
Bacteriophage Lysin and Antibiotic Combinations Against Gram Positive Bacteria
6 May 21
The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
Raymond SCHUCH, Robert C. NOWINSKI, Michael WITTEKIND, Han LEE, Brent SCHNEIDER
Filed: 5 Jan 21
Utility
Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
27 Apr 21
The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL).
Raymond Schuch
Filed: 30 Jan 20
Utility
Identification of Lysins and Derivatives Thereof with Bactericidal Activity Against Pseudomonas Aeruginosa
25 Mar 21
Disclosed are novel lysin polypeptides active against Gram-negative bacteria, particularly P. aeruginosa, pharmaceutical compositions containing them and methods for their use to treat Gram-negative bacterial infections and more generally to inhibit the growth, or reduce the population, or kill Gram-negative bacteria, including without limitation disrupting biofilms formed by such bacteria.
Raymond SCHUCH, Chiara INDIANI
Filed: 12 Dec 18
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
18 Feb 21
The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs.
Raymond SCHUCH
Filed: 29 Mar 19
Utility
MODIFIED PlySs2 LYSINS AND USES THEREOF
4 Feb 21
Disclosed herein are modified lysin polypeptides thereof comprising at least one amino acid substitution as compared to a wild-type PlySs2 lysin polypeptide having an amino acid sequence of SEQ ID NO: 1, wherein the at least one amino acid substitution is in the CHAP domain and/or the SH3b domain, and wherein the modified lysin polypeptide or fragment thereof inhibits the growth, tin reduces the population, or kills at least one species of Gram-positive bacteria.
Raymond SCHUCH, Chiara INDIANI, Michael WITTEKIND
Filed: 26 Feb 19
Utility
Bacteriophage Lysin and Antibiotic Combinations Against Gram Positive Bacteria
14 Jan 21
The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
Raymond SCHUCH, Robert C. NOWINSKI, Michael WITTEKIND, Han LEE, Brent SCHNEIDER
Filed: 25 Sep 20
Utility
Lysin Polypeptides Active Against Gram-negative Bacteria
2 Dec 20
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa.
Raymond SCHUCH, Simon HOFFENBERG, Michael WITTEKIND
Filed: 8 Jul 20
Utility
Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
30 Nov 20
The present invention provides components, assays and methods for evaluating antibacterial effectiveness and determining minimal inhibitory concentration (MIC) of polypeptides, including lysin polypeptides, that kill bacteria.
Raymond Schuch
Filed: 11 May 17
Utility
Bacteriophage lysin and antibiotic combinations against gram positive bacteria
26 Oct 20
The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
Filed: 8 May 13
Utility
Lysin polypeptides active against Gram-negative bacteria
17 Aug 20
The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa.
Raymond Schuch, Simon Hoffenberg, Michael Wittekind
Filed: 15 Sep 16
Utility
Lysin-antimicrobial Peptide (Amp) Polypeptide Constructs, Lysins, Isolated Polynucleotides Encoding Same and Uses Thereof
20 May 20
The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL).
Raymond Schuch
Filed: 29 Jan 20
Patents are sorted by USPTO publication date, most recent first